The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 7 March 2013 up to and including 13 March 2013 the Company bought 16080 own shares representing 0.012% of the share capital of the Company, to the total value of BGN 36047.53 on the Bulgarian Stock Exchange. The average price per share was BGN 2.24.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3637179, representing 2.755% of the share capital of the Company.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 14 March 2013 up to and including 20 March 2013 the Company bought 15688 own shares representing 0.012% of the share capital of the Company, to the total value of BGN 3578,38 on the Bulgarian Stock Exchange. The average price per share was BGN 2.28.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3652867, representing 2.767% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 19 December 2013 up to and including 8 January 2014 the Company bought 34 045 own shares representing 0.026% of the share capital of the Company, to the total value of 133 491.80 BGN on the Bulgarian Stock Exchange. The average price per share was 3.92 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 488 911, representing 4.16% of the share capital of the Company.
Sopharma AD (the “Company”) notifies that for December 2013 the Company recorded an increase of sales revenues of 63% compared to the same period of 2012, including 31% increase of domestic sales and 102% increase of export sales.
During the past year Sopharma AD recorded an increase of sales revenues of 3%, including 7% increase of domestic sales and 1% increase of export sales compared to 2012.
SOPHARMA AD (the “Company”) hereby informs that from 9 January 2014 up to and including 15 January 2014 the Company bought 18 313 own shares representing 0.014% of the share capital of the Company, to the total value of 72 711.42 BGN on the Bulgarian Stock Exchange. The average price per share was 3.97 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 507 224, representing 4.17% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 16 January 2014 up to and including 22 January 2014 the Company bought 9 839 own shares representing 0.007% of the share capital of the Company, to the total value of 38 910.92 BGN on the Bulgarian Stock Exchange. The average price per share was 3.95 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 517 063, representing 4.18% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 23 January 2014 up to and including 29 January 2014 the Company bought 5 523 own shares representing 0.004% of the share capital of the Company, to the total value of 21 825.32 BGN on the Bulgarian Stock Exchange. The average price per share was 3.95 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 522 586, representing 4.18% of the share capital of the Company.
Sopharma AD (the “Company”) notifies that for January 2014 the Company recorded an increase of sales revenues of 6% compared to the same period of 2013, including 2% increase of domestic sales and 9% increase of export sales.
SOPHARMA AD (the “Company”) hereby informs that from 30 January 2014 up to and including 5 February 2014 the Company bought 6 886 own shares representing 0.005% of the share capital of the Company, to the total value of 27 221.75 BGN on the Bulgarian Stock Exchange, the average price per share was 3.95 BGN and sold 511 589 own shares representing 0.39% of the share capital of the Company, to the total value of 2 174 003.21 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.
Sopharma AD (the “Company”) announces that on 7 February 2014 the Company received a notification for the acquisition of 4 230 000 shares, representing 3.20 % of its capital, by Rompharm Company OOD. After the transaction the share of Rompharm Company OOD in the capital of Sopharma AD reached 17.60%. The registration date of the transaction in the Central Depository AD, Sofia is 2 February 2014.
We would like to use cookies to better understand your use of this website. This helps us improve your future experience when visiting our website. If you continue your visit on our website, we shall assume that you agree with the cookies used. Detailed information on the use of cookies on this website and how to manage or withdraw your consent at any time, can be found in our